Inventor · disambiguated record
Jonathan W. Nyce
Also filed as: NYCE JONATHAN W · NYCE JONATHAN WESLEY
15 granted patents·22 pending applications·621 citations·filing 1994–2018
95Inventor score
Files withUNIV EAST CAROLINA15NYCE JONATHAN W4NYCE JONATHAN WESLEY4EPIGENESIS PHARMACEUTICAL INC1EPIGENESIS PHARMACEUTICALS LLC1
Top patents by PatentIndex Score
37 records- 0196US6087351AMethod for reducing adenosine levels with a dehydroepiandrosterone and optionally a ubiquinoneUNIV EAST CAROLINA·Filed 1997·Granted Jul 11, 2000·126 cites·72 claims
- 0291US6432924B1Method of treating disorders characterized by overexpression of cytidine deaminase or deoxycytidine deaminaseUNIV EAST CAROLINA·Filed 2000·Granted Aug 13, 2002·36 cites·103 claims
- 0391US6040296ASpecific antisense oligonucleotide composition & method for treatment of disorders associated with bronchoconstriction and lung inflammationUNIV EAST CAROLINA·Filed 1995·Granted Mar 21, 2000·116 cites·63 claims
- 0489US7034007B1Low adenosine anti-sense oligonucleotide, compositions, kit & method for treatment of airway disorders associated with bronchoconstriction, lung inflammation, allergy(ies) & surfactant depletionUNIV EAST CAROLINA·Filed 2000·Granted Apr 25, 2006·38 cites·12 claims
- 0589US6670349B1Composition & method for altering levels of or sensitivity to adenosine with a dehydroepiandrosterone &/or a ubiquinoneUNIV EAST CAROLINA·Filed 2000·Granted Dec 30, 2003·24 cites·70 claims
- 0689US5660835AMethod of treating adenosine depletionUNIV EAST CAROLINA·Filed 1995·Granted Aug 26, 1997·56 cites·19 claims
- 0784US5527789AMethod of inhibiting carcinogenesis by treatment with dehydroepiandrosterone and analogs thereofUNIV EAST CAROLINA·Filed 1994·Granted Jun 18, 1996·75 cites·19 claims
- 0882US7456161B2Use of DHEA and DHEA-sulfate for the treatment of chronic obstructive pulmonary diseaseEPIGENESIS PHARMACEUTICALS LLC·Filed 2003·Granted Nov 25, 2008·18 cites·24 claims
- 0981US6025339AComposition, kit and method for treatment of disorders associated with bronchoconstriction and lung inflammationUNIV EAST CAROLINA·Filed 1996·Granted Feb 15, 2000·52 cites·77 claims
- 1075US6136791AAgent and method for treating disorders associated with cytidine deaminase or deoxycytidine deaminase overexpressionUNIV EAST CAROLINA·Filed 1996·Granted Oct 24, 2000·37 cites·87 claims
- 1170US5994315ALow adenosine agent, composition, kit and method for treatment of airway diseaseUNIV EAST CAROLINA·Filed 1995·Granted Nov 30, 1999·26 cites·105 claims
- 1269US2008292709A1Kits for dhea and dhea-sulfate for the treatment of chronic obstructive pulmonary diseaseNYCE JONATHAN W·Filed 2008·Application pending·0 cites
- 1366US2009054385A1Solid inhalation formulations of dehydroepiandrosterone derivativesUNIV EAST CAROLINA·Filed 2008·Application pending·0 cites
- 1466US2009053143A1Liquid inhalation formulations of dehydroepiandrosterone derivativesUNIV EAST CAROLINA·Filed 2008·Application pending·0 cites
- 1564US2006111306A1Dehydroephiandrosterone and ubiquinone compositions for treating asthma and bronoconstrictionNYCE JONATHAN W·Filed 2005·Application pending·0 cites
- 1659US2009258046A1Composition, formulations and kit for treatment of respiratory and lung disease with non-glucocorticoid steroids and/or ubiquinone and a bronchodilating agentNYCE JONATHAN W·Filed 2009·Application pending·0 cites
- 1757US2002119936A1Composition & method for reducing adenosine levels with a ubiquinone and optionally a dehydroepiandrosteroneFiled 2001·Application pending·0 cites
- 1856US7893044B2Composition and method for altering levels of or sensitivity to adenosine with analogs of dehydroepiandrosteroneEPIGENESIS PHARMACEUTICAL INC·Filed 2004·Granted Feb 22, 2011·0 cites·1 claims
- 1956US2004034029A1Composition and method for altering levels of or sensitivity to adenosine with a dehydroepiandrosteroneFiled 2003·Application pending·0 cites
- 2055US2002032160A1Compositions & formulations with an epiandrosterone or a ubiquinone & kits & their use for treatment of asthma symptoms & for reducing adenosine/adenosine receptor levelsFiled 2001·Application pending·0 cites
- 2154US2005014711A1Composition, formulations & methods for prevention and treatment of diseases and conditions associated with bronchoconstriction, allergy(ies) and inflammationFiled 2004·Application pending·0 cites
- 2251US6825174B2Composition, formulations & method for prevention & treatment of diseases and conditions associated with bronchoconstriction, allergy(ies) & inflammationUNIV EAST CAROLINA·Filed 1998·Granted Nov 30, 2004·8 cites·16 claims
- 2351US2003181353A1Composition & use as analgesic, anti-inflammatory, wound healing agent, for treatment of heart conditions, assessment of heart function & tissue & cell protection & healing & reperfusion, mood disorders & symptoms & sequelae of menopause & for inducing unconsciousness, sleep & anesthesiaFiled 2003·Application pending·0 cites
- 2450US2004092470A1Dry powder oligonucleotide formualtion, preparation and its usesFiled 2003·Application pending·0 cites
- 2550US2020129525A1Method to improve quality of life in non-primate animals by administration of Dehydroepiandrosterone Sulfate (DHEAS) sufficient to achieve primate-specific levels of circulating DHEAS that are not natural to the target speciesNYCE JONATHAN WESLEY·Filed 2018·Application pending·0 cites
- 2648US2003216329A1Composition, formulations & kit for treatment of respiratory & lung disease with dehydroepiandrosterone(s) steroid & an anti-muscarinic agent(s)Filed 2003·Application pending·0 cites
- 2748US2004049022A1Composition & methods for treatment and screeningFiled 2003·Application pending·0 cites
- 2847US2005070487A1Composition, formulations and kit for treatment of respiratory and lung disease with non-glucocorticoid steroids and/or ubiquinone and a bronchodilating agentFiled 2002·Application pending·0 cites
- 2946US2003202935A1Composition and formulations and their use as nociceptic, anti-axniolytic and anabolic agentsFiled 2000·Application pending·0 cites
- 3041US2017007619A1High Dose Dehydroepiandrosterone as Anticancer Treatment With Multi-faceted Reconstitution of Otherwise Depleted MetabolitesNYCE JONATHAN WESLEY·Filed 2015·Application pending·0 cites
- 3141US2017007620A1Method of replenishing steroid hormones in neutered mammals comprising administration of dehydroepiandrosterone (DHEA) and specific metabolites in order to increase steroid hormone levels from those of neutered mammals associated with high cancer risk, to steroid hormone levels of gonadally-intact mammals associated with reduced cancer risk, without inducing the side effects that would occur without metabolite supplementation.NYCE JONATHAN WESLEY·Filed 2015·Application pending·0 cites
- 3240US6426330B1Satiety inducing composition comprising Neuropeptide Y analogues and methods of inducing satiety and treating a disease or condition associated with itUNIV EAST CAROLINA·Filed 1999·Granted Jul 30, 2002·5 cites·73 claims
- 3339US2017009238A1System of interdependent anticancer antisense oligonucleotides targeting mRNAs the targets of which are NADPH-dependent, combined with one or more inhibitors of the Pentose Phosphate Pathway to deplete NADPHNYCE JONATHAN WESLEY·Filed 2015·Application pending·0 cites
- 3438US6075009ANeuropeptide Y analogues, compositions and methods of lowering blood pressureUNIV EAST CAROLINA·Filed 1995·Granted Jun 13, 2000·4 cites·79 claims
- 3535US2007021360A1Compositions, formulations and kit with anti-sense oligonucleotide and anti-inflammatory steroid and/or obiquinone for treatment of respiratory and lung disesaseNYCE JONATHAN W·Filed 2002·Application pending·0 cites
- 3634US2011045032A1Composition, formulations & kit for treatment of respiratory and lung disease with dehydroepiandrosterone(s) steroid & an anti-muscarinic agent(s)EPIGENESIS PHARMACEUTICALS LLC A DELAWARE CORP·Filed 2010·Application pending·0 cites
- 3729US2003104576A1Dna construct, composition, formulations & methods for making the construct & for modulating expressionFiled 1994·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Jonathan W. Nyce files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →